246 related articles for article (PubMed ID: 27918211)
1. New targeted therapies for malignant lymphoma based on molecular heterogeneity.
Horn H; Staiger AM; Ott G
Expert Rev Hematol; 2017 Jan; 10(1):39-51. PubMed ID: 27918211
[TBL] [Abstract][Full Text] [Related]
2. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
3. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
4. Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.
Witkowska M; Smolewski P
Immunotherapy; 2015; 7(1):37-46. PubMed ID: 25572478
[TBL] [Abstract][Full Text] [Related]
5. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
[TBL] [Abstract][Full Text] [Related]
6. Non-Hodgkin's lymphoma: the old and the new.
Cabanillas F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
[TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
Maxwell SA; Mousavi-Fard S
Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
[TBL] [Abstract][Full Text] [Related]
8. Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.
Jamil MO; Mehta A
Expert Rev Hematol; 2016 May; 9(5):471-7. PubMed ID: 26808217
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
[TBL] [Abstract][Full Text] [Related]
10. Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implications.
Frontzek F; Lenz G
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1059-1067. PubMed ID: 31645159
[No Abstract] [Full Text] [Related]
11. Targeting B-cell non Hodgkin lymphoma: New and old tricks.
Solimando AG; Ribatti D; Vacca A; Einsele H
Leuk Res; 2016 Mar; 42():93-104. PubMed ID: 26818572
[TBL] [Abstract][Full Text] [Related]
12. BCL6 as a therapeutic target for lymphoma.
Leeman-Neill RJ; Bhagat G
Expert Opin Ther Targets; 2018 Feb; 22(2):143-152. PubMed ID: 29262721
[TBL] [Abstract][Full Text] [Related]
13. [Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].
Miyazaki K
Rinsho Ketsueki; 2015 Oct; 56(10):2047-55. PubMed ID: 26458444
[TBL] [Abstract][Full Text] [Related]
14. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
Choe H; Ruan J
Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
[TBL] [Abstract][Full Text] [Related]
15. Treatment approaches of hard-to-treat non-Hodgkin lymphomas.
Nandagopal L; Mehta A
Expert Rev Hematol; 2017 Mar; 10(3):259-273. PubMed ID: 28094575
[TBL] [Abstract][Full Text] [Related]
16. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
17. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
18. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Epperla N; Fenske TS; Lazarus HM; Hamadani M
Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
[TBL] [Abstract][Full Text] [Related]
19. Double hit lymphoma: from biology to therapeutic implications.
Burotto M; Berkovits A; Dunleavy K
Expert Rev Hematol; 2016 Jul; 9(7):669-78. PubMed ID: 27166590
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for diffuse large B-cell lymphoma.
Mondello P; Younes A
Expert Rev Anticancer Ther; 2015 Apr; 15(4):439-51. PubMed ID: 25652253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
